References
- Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid
involvement with specific desquamation of the fingers and toes in
children. Arerugi 1967;16 :178–222.
- Daniels LB, Tjajadi MS, Walford HH, et al. Prevalence of Kawasaki
disease in young adults with suspected myocardial ischemia.Circulation 2012;125 :2447–53.
- Terai M, Shulman ST. Prevalence of coronary artery abnormalities in
Kawasaki disease is highly dependent on gammaglobulin dose but
independent of salicylate dose. J Pediatr1997;131 :888–93.
- Newburger JW, Sleeper LA, McCrindle BW, et al.Pediatric Heart Network
Investigators. Randomized trial of pulsed corticosteroid therapy for
primary treatment of Kawasaki disease. N Engl J Med2007;356 :663–75.
- Burns JC, Capparelli EV, Brown JA, et al. Intravenous gammaglobulin
treatment and retreatment in Kawasaki disease: US/Canadian Kawasaki
Syndrome Study Group. Pediatr Infect Dis J1998;17 :1144–8.
- Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk
factors associated with nonresponse to initial intravenous
immunoglobulin treatment among Kawasaki disease patients in Japan.Pediatr Infect Dis J 2008;27 :155–60.
- Furukawa T, Kishiro M, Akimoto K, et al.Effects of steroid pulse
therapy on immunoglobulin-resistant Kawasaki disease.Arch Dis
Child 2008;93 :142–6.
- Sundel RP, Burns JC, Baker A, et al. Gamma globulin re-treatment in
Kawasaki disease. J Pediatr 1993;123 :657–9.
- Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and
long term management of Kawasaki disease. Circulation2004;110 :2747–71.
- Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective
randomized trial of corticosteroids in primary therapy for Kawasaki
disease: clinical course and coronary artery outcome. J Pediatr2006; 149 :336–41.
- Wallace CA, French JW, Kahn SJ, et al. Initial intravenous Gamma
globulin treatment failure in Kawasaki disease. Pediatrics2000;105 :E78.
- Wright DA, Newburger JW, Baker A, et al. Treatment of immune
globulin-resistant Kawasaki disease with pulsed doses of
corticosteroids. J Pediatr 1996;128 :146–9.
- McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment,
and long-term management of Kawasaki disease:ascientific statement for
health professionals from the American Heart
Association.Circulation 2017;135 :e1–e73.
- Carlin JB, Doyle LW. Statistics for clinicians. 7: Sample size. J
Paediatr Child Health 2002; 38 :300-304.
- Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment and
long-term management of Kawasaki disease: a statement for health
professionals from the Committee on Rheumatic Fever, Endocarditis and
Kawasaki Disease, Council on Cardiovascular Disease in the Young,
American Heart Association[J]. Pediatrics2004;114 (6): 1708–33.
- Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous
immunoglobulin unresponsiveness in patients with Kawasaki disease.Circulation 2006;113 :2606–12.
- Wright DA, Newburger JW, Baker A, et al. Treatment of immune
globulin-resistant Kawasaki disease with pulsed doses of
corticosteroids. J Pediatr 1996;128 :146–9.
- Egami K, Muta H, Ishii M,et al. Prediction of resistance to
intravenous immunoglobulin treatment in patients with Kawasaki
disease. J Pediatr 2006;149 :237–40.
- Lang BA, Yeung RS, Oen KG, et al. Corticosteroid treatment of
refractory Kawasaki disease. J Rheumatol2006;33 :803–9.
- Sonoda K, Mori M, Hokosaki T, et al. Infliximab plus plasma exchange
rescue therapy in Kawasaki disease. J Pediatr 2014;164 : 1128–32.
- Wallace CA, French JW, Kahn SJ, et al. Initial intravenous
gammaglobulin treatment failure in Kawasaki disease. Pediatrics2000;105 :E78.
- Cohen S, Tacke CE, Straver B, et al. A child with severe relapsing
Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal
membrane oxygenation. Ann Rheum Dis 2012; 71 :
2059–61.
- Furusho K, Kamiya T, Nakano H,et al. High dose intravenous
gammaglobulin for Kawasaki disease.Lancet 1984;2 :1055–8.
- Kato H, Koike S, Yokoyama T.Kawasaki disease: effect of treatment on
coronary artery involvement. Pediatrics1979;63 :175–9.
- Teraguchi M, Ogino KY, Taniuchi S, et al. Steroid pulse therapy for
children with intravenous immunoglobulin therapy-resistant Kawasaki
disease: aprospective study.PediatrCardiol2013;34 (4):959–63.
- Shinohara M, Sone K, Tomomasa T, et al. Corticosteroids in the
treatment of the acute phase of Kawasaki disease. J Pediatr1999;135 :465–9.
- Chen S, Dong Y, Yin Y, et al. Intravenous immunoglobulin plus
corticosteroid to prevent coronary artery abnormalities in Kawasaki
disease: a meta-analysis. Heart 2013;99 :76–82.
- Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse
therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis
Child 2008;93 :142–6.
- MiuraM, Ohki H, YoshibaS, et al. Adverse effects of
methyl-prednisolone pulse therapy in refractory Kawasaki disease.Arch Dis Child 2005;90 (10): 1096–7.
- Zhang YL, Du ZD, Fu PP, et al. Curative effect observation of
different doses of intravenous gamma globulin or methylprednisolone in
children with unresponsive Kawasaki disease. Chinese Journal of
Evidence-Based Pediatrics 2013;8 (3): 220–3.